Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07078955

A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are ≥18 years of age;
  • Are willing and able to comply with all study procedures and restrictions and the visit schedule;
  • Have a self-reported history of dry eye prior to enrollment;
  • If a woman of childbearing potential (WOCBP): are non-lactating, have a negative urine pregnancy test (UPT), and agree to use an acceptable form of contraception for the duration of the study;

Exclusion criteria

  • Within 3 months prior to Visit 1, have participated in any other investigational study or used an investigational product or device;
  • Have any history of organ or bone marrow transplant, immunodeficiency disorder, human immunodeficiency virus, or hepatitis C, or any evidence of acute active hepatitis A (anti-hepatitis A virus immunoglobulin M);
  • Have any significant illness or condition that, in the opinion of the Investigator, could affect the study outcome measures. Such illnesses include (but are not limited to) Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, severe cardiopulmonary disease, poorly controlled hypertension or diabetes, or drug/alcohol addiction;
  • Within 12 months prior to Visit 1, have undergone any ocular surgical procedure, including laser-assisted in situ keratomileusis (LASIK) or a similar corneal refractive surgery;

Treatment and study plan

BRM421 Ophthalmic Solution, 0.03%

Drug

A topical drop of 0.03% BRM421 ophthalmic solution.

Artificial tear

Drug

A topical drop of Artificial Tear.

BRM421 Ophthalmic Solution, 0.06%

Drug

A topical drop of 0.06% BRM421 ophthalmic solution.

Primary outcomes

  1. Change from baseline in total corneal fluorescein staining (tCFS) score

    Time frame: 6 weeks

    Total corneal fluorescein staining (tCFS) score by using NEI Scale (0-20, higher scores mean a worse outcome)

Study contacts

Contact information is provided by the study sponsor or research team.

Ning Alin Associate Director

CONTACT

[email protected]

+886-2-26598586

Sponsors and collaborators

Lead sponsor

BRIM Biotechnology Inc.

Industry

Registry information

Official study title

A Phase 2, Multicenter, Randomized, Open-Labeled, Artificial Tear-Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jul 22, 2025
Registry last updated
Oct 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.